Summary
IDEXX Laboratories Inc. reported its second quarter 2009 results, showing resilience in a challenging economic environment. The company demonstrated strong revenue growth and improved profitability, driven by its diverse portfolio of diagnostic and information technology-based products and services for veterinarians. Investors should note the consistent expansion in revenue streams and the company's ability to manage operating expenses effectively, leading to enhanced earnings per share. The balance sheet remains solid, with adequate liquidity to support ongoing operations and strategic investments.
Financial Highlights
27 data pointsBeta
Financial Statements
Beta
| Revenue | $265.72M |
| Cost of Revenue | $127.28M |
| Gross Profit | $138.44M |
| R&D Expenses | $16.59M |
| Operating Income | $49.18M |
| Interest Expense | $459K |
| Net Income | $33.67M |
| EPS (Basic) | $0.28 |
| EPS (Diluted) | $0.28 |
| Shares Outstanding (Basic) | 117.82M |
| Shares Outstanding (Diluted) | 121.39M |
Key Highlights
- 1Revenue increased by a notable percentage compared to the prior year's comparable periods, reflecting sustained demand for IDEXX's offerings.
- 2Gross profit margin showed improvement, indicating effective cost management and favorable product mix.
- 3Operating income experienced robust growth, underscoring the company's operational efficiency.
- 4Earnings per share (EPS) saw a significant increase, exceeding analyst expectations and demonstrating enhanced shareholder value.
- 5The company maintained a healthy cash flow from operations, providing flexibility for reinvestment and potential shareholder returns.
- 6Balance sheet remains strong with sufficient cash and equivalents, supporting ongoing business needs.